Alzheimer’s Diagnosis with a Blood Test? Full Scientific Review | Dr. Khushboo Verma скачать в хорошем качестве

Alzheimer’s Diagnosis with a Blood Test? Full Scientific Review | Dr. Khushboo Verma

A major shift in Alzheimer’s diagnosis just happened. The FDA recently cleared a blood-based biomarker test: the Lumipulse G pTau217/Aβ42 plasma ratio, as a tool to aid in detecting Alzheimer’s pathology. But what does this mean for clinical practice, diagnostic accuracy, and patient care? In this video, Dr. Khushboo Verma, behavioral neurologist and dementia researcher, takes you step by step through the science, the FDA’s approval process, and what clinicians need to know before ordering or interpreting this test. You’ll learn: 1. What the FDA’s 510(k) clearance really means 2. How the new blood test compares with PET and CSF testing 3. The diagnostic performance: sensitivity, specificity, predictive value 4. Why is this test not approved for screening asymptomatic patients 5. How the pTau217/Aβ42 ratio works—and why ratios are more reliable 6. What recent studies (ADNI, INTERCEPTOR) reveal about plasma biomarkers 7. The ethical and clinical implications for neurologists and primary care providers This is a deep-dive explanation, designed for physicians, scientists, and thoughtful viewers interested in the future of Alzheimer’s diagnostics. | Timestamp | Chapter | | --------- | ----------------------------------------------------- | | 00:00:29 | FDA Announces First Alzheimer’s Blood Test | | 00:00:49 | What the FDA News Release Actually Says | | 00:01:07 | Current Diagnostic Workflow (MOCA / MMSE → PET / CSF) | | 00:01:58 | 2024 Biomarker Accuracy Criteria (Alzheimer’s Assoc.) | | 00:03:00 | Rise of Blood Biomarkers & pTau-217 “Star Performer” | | 00:04:48 | Many Assays, One Ratio: Lumipulse pTau217 / Aβ42 | | 00:06:00 | Chemiluminescence Assay—Step-by-Step Walk-through | | 00:10:00 | FDA Clearance Paths: PMA, De Novo, 510(k) | | 00:11:34 | CSF Ratio Validation Using the ADNI Dataset | | 00:15:00 | Predictive Values, Hook Effect & Test Robustness | | 00:17:29 | FDA Definitions: Aid-Diagnosis vs. Screening | | 00:22:00 | Who the Blood Test Is For & Key Performance Numbers | | 00:25:11 | Multi-Centre Plasma Study Results (\~500 Patients) | | 00:26:50 | INTERCEPTOR Project (Italy) — Design & Goals | | 00:29:00 | Plasma vs CSF Concordance Findings | | 00:32:00 | Correlation Graphs: Aβ42, Aβ40 & Ratios | | 00:35:00 | Boxplots: Discriminating AD vs. Non-AD Pathology | | 00:38:00 | Adding Tau Status — Four Clinical Phenotypes | | 00:42:00 | Why Ratios Beat Single Biomarkers | | 00:45:12 | ROC Curves: Top Performers & Combo Models | | 00:50:00 | Practical Use-Cases, Limitations & Ethics | | 00:52:30 | Screening Controversy in Asymptomatic Adults | | 00:54:45 | Closing Thoughts & Dedication to Patients | For more evidence-based updates on dementia care, neurology, and aging, subscribe to the channel and share this video with colleagues. ⚠️ Disclaimer: This video is intended for educational purposes only and does not constitute medical advice. Please consult your healthcare provider before making any changes to your lab tests, medications, or treatment plans. #Bloodtest #AlzheimersDisease #Dementia #TheDementiaDoctor #MentalHealth #DoctorKhushboo #DoctorVerma